Waist circumference, not BMI, was tied to increased risk for adiposity-related heart failure, and the association was significantly mediated by systemic inflammation, a speaker reported.
Systemic inflammation — measured as high-sensitivity C-reactive protein levels — mediated more than one-quarter of the risk for adiposity-related HF associated with elevated waist circumference and waist-to-height ratio, according to a presentation at the American Heart Association’s EPI | Lifestyle Scientific Sessions.
“This research helps us understand why some people develop heart failure despite having a

A GIP/GLP-1/glucagon triple agonist reduced HbA1c by up to 1.9 percentage points at 40 weeks for adults with type 2 diabetes, according to topline results from the TRANSCEND-T2D-1 trial.
Retatrutide (Eli Lilly) is a once-weekly injectable medication currently under investigation to treat type 2 diabetes, obesity and a wide range of other conditions. The phase 3 TRANSCEND-T2D-1 trial enrolled 537 adults diagnosed with type 2 diabetes who were unable to achieve glycemic control with diet and exercise alone. All participants had an HbA1c of 7% to 9.5% at baseline, a BMI of 23 kg/m2 or higher, had

Tirzepatide provided a larger reduction in HbA1c and greater improvements in multiple cardiometabolic parameters compared with conventional care for adults recently diagnosed with type 2 diabetes, according to a speaker.
Stefano Del Prato, MD, professor of endocrinology and metabolism at the University of Pisa School of Medicine and chief of the section of diabetes at University of Pisa in Italy, said multiple studies in the SURPASS clinical trial program revealed tirzepatide (Mounjaro, Eli Lilly) lowered HbA1c to below 5.7% for more than half of adults with type 2 diabetes, with the odds of

For most children with complicated pneumonia, a less aggressive treatment approach is favored for those with small or moderate pleural effusions, according to updated guidance.
The Infectious Diseases Society of America and the Pediatric Infectious Disease Society recently published updated guidance for managing community-acquired pneumonia with parapneumonic effusion in children aged 3 months to 18 years — the first major update since 2011.
The new guidelines have been in development for the past 5 years, and researchers are still working on recommendations for uncomplicated pneumonia,

With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease treatments, we are talking about treating meibomian gland dysfunction and evaporative dry eye.
For decades, meibomian gland dysfunction treatment began and ended with warm compresses and baby shampoo scrubs. Medical advice consisted of insisting that your patient use Johnson’s baby shampoo. Perhaps the first real breakthrough was the discovery of the presence of biofilm on the lid surface, typically associated with staph species. As is so often the case, research led by Hank

Roflumilast cream 0.05% was well-tolerated and effective for the long-term treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a study published in Pediatric Dermatology.
“Topical therapies are used across the board for atopic dermatitis, but when it comes to younger children with atopic dermatitis, there is a limited armamentarium of treatments,” Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, vice chair of the department of dermatology at University of California San Diego and a member

In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the pros and cons of trastuzumab deruxtecan in neoadjuvant and adjuvant settings.
Tarantino said a debate he participated in on the topic at Miami Breast Cancer Conference helped him “focus some of his thoughts” on why using trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo), commonly called T-DXd, in the adjuvant setting may be the preferred strategy.
“I do think that makes sense because there are patients that can be spared [antibody-drug conjugates] in the neoadjuvant setting

Adults with diabetes had an elevated risk for dementia, with a higher risk among those with type 1 compared with type 2 diabetes, according to a study published in Neurology.
“Diabetes mellitus is well known to be associated with elevated dementia risk, but most prior studies have focused on type 2 diabetes or have not clearly distinguished between type 1 and type 2 diabetes mellitus,” Anna M. Pederson, MPH, data analyst at Boston University School of Public Health, told Healio.
The two types of diabetes are biologically distinct, and the scarcity of type 1 diabetes, which accounts for about 5%

There’s a moment every psychiatrist recognizes.
A patient sits down. You have 20 minutes. But their life is not 20 minutes wide.
You hold complexity in your mind and try to make a clean next step, listen for the story under the story, and scan for safety. You notice what’s missing. You decide what to ask next, what not to ask yet, and what to name.
Then, weeks later, whatever happened in that room gets flattened into a claim. A CPT code. A diagnosis code. A date. A place of service.
And we wonder why the system can’t tell the difference between careful, evidence-informed psychiatry and someone

Finerenone demonstrated safety and reduced albuminuria for patients with chronic kidney disease, type 2 diabetes and a history of nephrectomy, according to study findings published in Clinical Journal of the American Society of Nephrology.
In the FIDELITY trial, finerenone (Kerendia, Bayer), a selective mineralocorticoid receptor antagonist, was associated with reduced risks for kidney and CV events and a lower urine albumin-to-creatinine ratio (UACR) among patients with CKD and type 2 diabetes, according to Jair Munoz Mendoza, MD, associate professor of clinical medicine in the division of